ProPhase Labs, Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value
Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.
Your own DCF model
A full discounted-cash-flow model of ProPhase Labs, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Pharmaceutical
Multiples of its companies with a market value at most 60 days old, times ProPhase Labs, Inc.'s own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | ProPhase Labs, Inc. | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| Price to sales | 1.5× / 3.5× / 6.6× | — | revenue $4 M | $7 M to $29 M | 69 |
| Price to book | 2.1× / 4.1× / 8.1× | — | book equity $4 M | $7 M to $29 M | 63 |
Against its own history
ProPhase Labs, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to May 2026, each against its own median.
Price to sales
1.4×Now below its median of 2.4×, in the bottom quarter of its range; range 0.7× to 10.8× over 18 months.
Price to book
1.6×Now below its median of 2.0×; range 0.2× to 11.1× over 21 months.
As of May 15, 2026
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | $4 M | $-15 M | $-8 M | $0 M | $-8 M | — | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | $7 M | $-53 M | $-18 M | $1 M | $-18 M | — | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $35 M | $-17 M | $-12 M | $2 M | $-14 M | $1 M | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $123 M | $18 M | $29 M | $4 M | $25 M | $-9 M | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $79 M | $6 M | $-14 M | $4 M | $-18 M | — | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $15 M | $-2 M | $-3 M | $2 M | $-4 M | — | SEC annual report (10-K, 20-F) |